CurrentCignaPolicy N/A

Dermatology - Opzelura Prior Authorization Policy

Cigna prior authorization policy describing medical necessity criteria, durations, and exclusions for coverage of Opzelura cream (ruxolitinib 1.5%) for dermatology indications (atopic dermatitis and nonsegmental vitiligo) for benefit plans administered by Cigna companies.

Policy Summary

PayerCigna

PolicyDermatology - Opzelura Prior Authorization Policy

Policy CodePolicy N/A

Change TypeRevised criteria and appendix updates

Effective DateN/A

Next Review DateN/A

Key ActionDocument prior trial(s) of specified topical corticosteroid or topical calcineurin inhibitor, treatment duration, and inadequate efficacy; request prior authorization and ensure specialist prescription or consultation as required.

SourceLink

POLICY UPDATE CHANGES

Atopic dermatitis criteria were revised to require a trial of either one medium-/medium-high/high-/super-high-potency prescription topical corticosteroid OR a topical calcineurin inhibitor (previously required trial of both).

Vitiligo criteria were revised to require a trial of either one high-/super-high-potacity prescription topical corticosteroid OR a topical calcineurin inhibitor (previously required trial of both).

Appendix updated to include additional biologic agents and JAK inhibitors as examples of therapies not to be combined with Opzelura.

2FDA-approved indications covered

≤20%Max BSA for atopic dermatitis use

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria for Opzelura (ruxolitinib 1.5% cream)

Medically Necessary — Atopic Dermatitis (FDA-approved)

Approve for 8 weeks if ALL of the following are met:

ALL of the following

Patient is ≥ 12 years of age
Prescriber states patient has mild to moderate atopic dermatitis
Atopic dermatitis involvement estimated to affect ≤ 20% of body surface area (BSA)
PRIOR TOPICAL THERAPY
- Option i: Prior topical corticosteroid
  - Patient has tried at least one medium-, medium-high-, high-, and/or super-high-potency prescription topical corticosteroid
  - That topical corticosteroid was applied daily for at least 28 consecutive days≥ 28 consecutive days
  - Prescriber documents inadequate efficacy with that topical corticosteroid therapy
- Option ii: Prior topical calcineurin inhibitor
  - Patient has tried at least one topical calcineurin inhibitor (e.g., tacrolimus ointment, pimecrolimus cream)
  - That topical calcineurin inhibitor was applied daily for at least 28 consecutive days≥ 28 consecutive days
  - Prescriber documents inadequate efficacy with that topical calcineurin inhibitor therapy
Medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist
Specialist involvement required due to evaluation/monitoring needs

ref

title

ref_raw

Medically Necessary — Vitiligo (FDA-approved)

Approve for 6 months if ALL of the following are met:

ALL of the following

Patient is ≥ 12 years of age
Patient has nonsegmental vitiligo
Vitiligo involvement estimated to affect ≤ 10% of body surface area (BSA)
PRIOR TOPICAL THERAPY
- Option i: Prior high-potency topical corticosteroid
  - Patient has tried at least one high- and/or super-high-potency prescription topical corticosteroid

Not Medically Necessary / Exclusions

Opzelura is considered not medically necessary for any uses not listed above, including but not limited to:

ANY of the following

Concurrent use with therapeutic biologics (examples listed in Appendix) or with other JAK inhibitors
Combination use not recommended; safety/efficacy unknown
Concurrent use with other potent immunosuppressants (e.g., azathioprine, cyclosporine)
Combination use not recommended; safety/efficacy unknown
Treatment of alopecia (not indicated; pivotal data do not show benefit)
Treatment of plaque psoriasis (not indicated; insufficient data)

Product and Coding Information

Drug (product covered)NDC|proprietaryCovered

Opzelura (ruxolitinib 1.5% cream)

Topical 1.5% ruxolitinib cream (Incyte) — subject of this PA policy

What Providers Must Do / Watch For

Prior Authorization

Prior authorization required

Prior authorization is recommended for Opzelura (ruxolitinib 1.5% cream). Approvals are provided for 8 weeks when used for atopic dermatitis and for 6 months when used for nonsegmental vitiligo.

Opzelura (ruxolitinib 1.5% cream)

Documentation Required

Document prior topical therapy and response

Document the prior trial(s) of the required topical therapy, the duration of that therapy, and the prescriber’s assessment that the topical therapy demonstrated inadequate efficacy. Use the duration thresholds specified in the criteria (atopic dermatitis: ≥28 consecutive days; vitiligo: ≥12 weeks [intermittent or continuous]).

Atopic dermatitis topical corticosteroid or topical calcineurin inhibitor: applied daily ≥28 consecutive days
Vitiligo topical corticosteroid or topical calcineurin inhibitor: applied daily ≥12 weeks

Clinical and Safety Context

Opzelura (ruxolitinib 1.5% cream) is a topical JAK1/JAK2 inhibitor indicated for the short-term, non-continuous topical treatment of mild to moderate atopic dermatitis and for the topical treatment of nonsegmental vitiligo in patients aged ≥ 12 years. For atopic dermatitis, the product is applied twice daily to affected areas up to a maximum of ≤ 20% body surface area (BSA); patients should be re-evaluated if signs and symptoms do not improve within 8 weeks. For vitiligo, Opzelura is applied twice daily to affected areas up to a maximum of ≤ 10% BSA; patients may require more than 24 weeks of treatment and should be re-evaluated if repigmentation is not clinically meaningful after 24 weeks of therapy.

Initial authorization durations in this policy align with the indications: 8 weeks for atopic dermatitis and 6 months (authorize as months equal to 30 days) for vitiligo when the coverage criteria are met and prescriber documentation supports prior topical therapy and inadequate response.

Opzelura carries a Boxed Warning for the risk of serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events (MACE), and thrombosis; other important warnings include cytopenias and lipid elevations. Because of these risks, the prescribing information recommends careful patient evaluation and monitoring when using the product.

Key Numeric Thresholds and Defined Terms

Coverage Thresholds

Atopic dermatitis maximum treated body surface area≤ 20% BSA

Vitiligo maximum treated body surface area≤ 10% BSA

Atopic dermatitis prior topical corticosteroid duration requirement≥ 28 consecutive days

Prior topical calcineurin inhibitor duration (AD)≥ 28 consecutive days

Vitiligo prior topical corticosteroid duration requirement≥ 12 weeks (intermittent or continuous)

Prior topical calcineurin inhibitor duration (vitiligo)≥ 12 consecutive weeks

Appendix: Examples of Agents Not to Combine with Opzelura

The Appendix lists examples of therapeutic biologics and other JAK inhibitors that should NOT be used concurrently with Opzelura because combination use was not permitted in pivotal studies and safety/efficacy of combinations are unknown. Examples include, but are not limited to, biologics such as adalimumab (Humira® and biosimilars), infliximab (Remicade® and biosimilars), ustekinumab (Stelara® and biosimilars), dupilumab (Dupixent®), and others listed in the Appendix, as well as oral or systemic JAK inhibitors and JAK-pathway agents such as tofacitinib (Xeljanz®), baricitinib (Olumiant®), upadacitinib (Rinvoq®), deucravacitinib (Sotyktu™), ruxolitinib tablets (Jakafi®), deuruxolitinib (Leqselvi™), ritlecitinib (Litfulo®), and related agents named in the Appendix.

Claims for Opzelura used concurrently with these listed biologics, other JAK inhibitors, or other potent immunosuppressants (e.g., azathioprine, cyclosporine) are considered Not Medically Necessary under this policy and therefore may be denied. Providers must document that Opzelura will not be used in combination with excluded agents to avoid denial risk.

Policy Changes and Rationale

2025-06-25criteria revised (material)Latest

Atopic dermatitis and vitiligo criteria revised to require a trial of either a topical corticosteroid OR a topical calcineurin inhibitor (instead of previously requiring both); prior exceptions allowing omission of a topical corticosteroid trial for disease affecting face/eyes/skin folds/genitalia were removed.

2024-09-04appendix clarified

Appendix updated to include additional biologic agents and JAK inhibitors (added examples and biosimilars) as therapies not to be combined with Opzelura.

2023-08-16annual revision (no clinical criteria change)